NPACT- Naturally occuring Plant based Anticancerous Compound-Activity-Target DataBase

Compound: Saikosaponin D

TargetsGene NameGene IDCancerCell LinesIC50ED50EC50GI50RemarkReferences
BAXBCL2-associated X protein581Lung adenocarcinomaA549----The levels of Bax were investigated by Western analysis in untreated and treated A549. In the case of pro-apoptotic Bax protein, 20 AM Saikosaponin D increased Bax protein levels in contrast to the levels of the control cells, at 12, 24, and 48 h.15219811
CASP8caspase 8, apoptosis-related cysteine peptidase841Lung adenocarcinomaA549----The results showed that caspase-8 activity increased at 12 h, and reached maximum induction at 24 h in 20 AM Saikosaponin D treated A549 cells. Furthermore, our results showed that the antiproliferative activity and induction of apoptosis by Saikosaponin D were significantly decreased in the presence of inhibitor of caspase-8.15219811
CDKN1Acyclin-dependent kinase inhibitor 1A (p21, Cip1)1026Lung adenocarcinomaA549----Increase in p21/WAF1 protein was apparent at 6 h and reached maximum induction at 24 h in Saikosaponin D treated A549 cells. Moreover, the induction of p21/WAFr1 was in a dose-dependent manner.15219811
FasTNF receptor superfamily, member 7355Lung adenocarcinomaA549----As observed in the induction of p21/WAF1, the expression of Fas/APO-1 was detected in A549 cells at 6 h after Saikosaponin D treatment. Maximum Fas/APO-1 was detected at 24 h. It is suggested that the induction of Fas/APO-1 in Saikosaponin D-treated A549 cells might be related to the activation of p53.15219811
TP53tumor protein p537157Lung adenocarcinomaA549----The up-regulation of p53 by Saikosaponin D can be appreciated from the 6th hour of treatment, the highest effect being observed after 12 hours of incubation with the drug. Comparison of the results between apoptotic response and induction of p53 indicated that the up-regulation of p53 occurred at an early stage of Saikosaponin D-mediated apoptotic process.15219811

 






Copyright © 2012. Subhash M. Agagrwal. All Rights Reserved.